SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Deals
BMS Backs Out of $1.5B Deal, Returns Rights to Agenus for Bispecific Antibody
As part of a pipeline realignment, Bristol Myers Squibb is returning the rights to Agenus for its proprietary TIGIT bispecific antibody program and terminating their 2021 license, development and commercialization agreement.
August 5, 2024
 · 
2 min read
 · 
Tyler Patchen
Sign outside BioNTech's building in Germany
Earnings
BioNTech’s Losses Jump Fourfold in Q2 Amid COVID-19 Cliff, Shift to Cancer
BioNTech on Monday reported nearly $885 million in losses in the second quarter of 2024, compared to $208.5 million during the same period last year.
August 5, 2024
 · 
3 min read
 · 
Tristan Manalac
Eli Lilly's world headquarters in Indianapolis
Drug shortages
Lilly’s Mounjaro and Zepbound No Longer on FDA Drug Shortage List
All doses of Eli Lilly’s type 2 diabetes medication Mounjaro and weight-loss drug Zepbound are now available, according to an update on Friday to the FDA’s drug shortage database.
August 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of the FDA's office in Maryland
Adcomms
Zevra Gains Support of Adcomm, Clears Hurdle for Potential Rare Disease Approval
An FDA advisory committee agreed on Friday that Zevra Therapeutics had provided sufficient efficacy data supporting the approval of arimoclomol for Niemann-Pick disease type C.
August 5, 2024
 · 
2 min read
 · 
Tristan Manalac
A closed sign hanging on the door of a business
Business
Big Pharma-Backed Ribon Therapeutics Shuts Down Business Operations
Despite having an impressive roster of high-profile supporters, including AbbVie, BMS, J&J, Novartis and Pfizer, PARP-focused Ribon has called it quits after nearly a decade in business.
August 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Illustration of a brain with DNA strands in the background
Opinion
Cell and Gene Therapy Shows Early Promise Against Alzheimer’s—But Challenges Remain
Longeveron and Lexeo Therapeutics are working on CGT therapies to treat Alzheimer’s disease, but it’s not clear whether they have a better chance of success than traditional approaches.
August 5, 2024
 · 
4 min read
 · 
Jia Jie Chen
Brain and vaccine vials
Alzheimer’s disease
New Wave of Alzheimer’s Therapies Actively Engage the Immune System
Active immune therapies hold promise for preventing or slowing disease onset, but some experts warn of potential safety risks.
August 5, 2024
 · 
5 min read
 · 
Gail Dutton
A hand cutting a slice of DNA
CRISPR
Small Enzymes, Giant Leaps: CRISPR’s Next-Generation Approach to Genetic Diseases
Ultracompact CRISPR systems, which are in some cases one-third the size of Cas9, are being designed to be more specific and enable in vivo gene editing in difficult to reach tissues.
August 5, 2024
 · 
4 min read
 · 
Greg Slabodkin
Syringe resting on top of a vaccine vial, with more vaccine bottles in the background
Vaccines
RSV Vaccine Makers Hit Hard by New CDC Guidelines
GSK, Moderna and Pfizer are all looking at potential respiratory syncytial virus vaccine sales slumps thanks to recently updated CDC guidelines regarding the use of RSV shots in seniors.
August 2, 2024
 · 
3 min read
 · 
Greg Slabodkin
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS